Lasmiditan in Patients with Common Migraine Comorbidities: A Post hoc, Safety, and Efficacy Analysis of Two Phase 3 Randomized Clinical Trials

被引：0
|
作者：
Clemow, D. B. [1 ]
Baygani, S. K. [1 ]
Hauck, P. M. [1 ]
Hultman, C. B. [1 ]
Wilhelm, S. [2 ]
机构：
[1] Eli Lilly & Co, Indianapolis, IN 46285 USA
[2] Lilly Deutschland GmbH, Bad Homburg, Germany
来源：
EUROPEAN JOURNAL OF NEUROLOGY | 2020年 / 27卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
EPO3130
引用
收藏
页码：1094 / 1094
页数：1
相关论文
共 50 条
  • [1] Lasmiditan in Patients with Common Migraine Comorbidities: A Post hoc, Safety, and Efficacy Analysis of Two Phase 3 Randomized Clinical Trials
    Clemow, David
    Baygani, Simin
    Hauck, Paula
    Hultman, Cory
    [J]. NEUROLOGY, 2020, 94 (15)
  • [2] Lasmiditan in patients with common migraine comorbidities: apost hocefficacy and safety analysis of two phase 3 randomized clinical trials
    Clemow, David B.
    Baygani, Simin K.
    Hauck, Paula M.
    Hultman, Cory B.
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2020, 36 (11) : 1791 - 1806
  • [3] Lasmiditan in Japanese Patients with Common Migraine Comorbidities or Concomitant Medications: A Post Hoc Safety and Efficacy Analysis from the MONONOFU Study
    Kitamura, Shigekazu
    Imai, Noboru
    Tanji, Yuka
    Ozeki, Akichika
    Komori, Mika
    [J]. JOURNAL OF PAIN RESEARCH, 2023, 16 : 1725 - 1738
  • [4] Sustained responses to lasmiditan: Results from post-hoc analyses of two Phase 3 randomized clinical trials for acute treatment of migraine
    Doty, Erin Gautier
    Krege, John H.
    Jin, Leah
    Raskin, Joel
    Singh, Rashmi B. Halker
    Kalidas, Kavita
    [J]. CEPHALALGIA, 2019, 39 (12) : 1569 - 1576
  • [5] Safety Findings in Lasmiditan as a Novel Acute Treatment of Migraine in Chinese Patients: A Post Hoc Analysis of the Randomized Controlled Phase 3 CENTURION Trial
    Jiying Zhou
    Guogang Luo
    Yuming Xu
    Xiaosu Yang
    Xiaoping Pan
    Zhao Dong
    Shiying Zhong
    Hui Liu
    Fei Ji
    Shengyuan Yu
    [J]. Advances in Therapy, 2022, 39 : 5229 - 5243
  • [6] Safety Findings in Lasmiditan as a Novel Acute Treatment of Migraine in Chinese Patients: A Post Hoc Analysis of the Randomized Controlled Phase 3 CENTURION Trial
    Zhou, Jiying
    Luo, Guogang
    Xu, Yuming
    Yang, Xiaosu
    Pan, Xiaoping
    Dong, Zhao
    Zhong, Shiying
    Liu, Hui
    Ji, Fei
    Yu, Shengyuan
    [J]. ADVANCES IN THERAPY, 2022, 39 (11) : 5229 - 5243
  • [7] Efficacy and safety of lasmiditan in patients using concomitant migraine preventive medications: findings from SAMURAI and SPARTAN, two randomized phase 3 trials
    Loo, Li Shen
    Ailani, Jessica
    Schim, Jack
    Baygani, Simin
    Hundemer, Hans-Peter
    Port, Martha
    Krege, John H.
    [J]. JOURNAL OF HEADACHE AND PAIN, 2019, 20 (1): : 84
  • [8] Efficacy and safety of lasmiditan in patients using concomitant migraine preventive medications: findings from SAMURAI and SPARTAN, two randomized phase 3 trials
    Li Shen Loo
    Jessica Ailani
    Jack Schim
    Simin Baygani
    Hans-Peter Hundemer
    Martha Port
    John H. Krege
    [J]. The Journal of Headache and Pain, 2019, 20
  • [9] Sustained efficacy of lasmiditan: Results from phase 3 randomized clinical trials for acute treatment of migraine
    Doty, E. G.
    Krege, J.
    Jin, L.
    Raskin, J.
    Singh, R. Halker
    Kalidas, K.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2019, 26 : 139 - 139
  • [10] Efficacy and safety of fremanezumab in patients with migraine and obesity: post-hoc analysis of the phase 3 HALO-LTS and FOCUS clinical trials
    Irimia Sieira, P.
    Torphy, B.
    Ortega, M.
    Barash, S.
    Krasenbaum, L. J.
    Akcicek, H.
    Smith, M.
    Ning, X.
    Campos, V. Ramirez
    [J]. JOURNAL OF HEADACHE AND PAIN, 2024, 25
12345